Novel Food and CBD: What It Means for Oils, Gummies and Food Products

Why CBD foods fall under the Novel Food framework

CBD food products have a different route to market from cosmetics, e-liquids or non-food flower products. For professional buyers, the first question is whether the specific ingredient and intended food use have the required authorisation, not whether a similar product is already on sale.

This framework is set out in Regulation (EU) 2015/2283. It requires a Novel Food authorisation before a relevant food ingredient can be placed on the market. The assessment is not a packaging or labelling exercise. It concerns the safety of the ingredient, its proposed conditions of use and the information available to support those conditions.

For wholesalers, retailers and distributors, the format matters as much as the cannabinoid. Treat ingestible CBD as a separate commercial category from flower, resin or vape products.

The position of CBD oils, gummies and supplements in France

The French agriculture ministry’s statement of 20 May 2026 confirmed that unauthorised foods containing or promoting CBD must be withdrawn from the market. It announced wider controls following targeted checks already in place since 2023. The ministry distinguishes hemp seeds and their derivatives, and leaves solely for aqueous infusion, from novel foods. Those exceptions have conditions, including no enrichment with cannabinoid extracts; they do not authorise CBD-added foods.

This point matters for businesses that have historically sold several CBD categories side by side. A product may look familiar to consumers and may have circulated in commercial channels for years, but that does not itself establish a valid route to market under the Novel Food Regulation.

For French professional buyers, a CBD oil or gummy should not be treated as an ordinary restocking line merely because a supplier provides a specification sheet, batch number or laboratory result. Lab testing and Novel Food authorisation are separate matters. A certificate of analysis can be relevant to composition and traceability, but it does not replace a market authorisation for an ingestible CBD ingredient.

What remains distinct from ingestible CBD products

Raw CBD flowers and resin for non-ingestible use, e-liquids and cosmetics remain distinct from foods. Their rules are not identical to Novel Food. They still need the applicable THC threshold, documentation and lawful presentation for the market where they are sold.

Do not assume that because a flower or a resin can be sold, an oil marketed for ingestion can be sold on the same basis. Classification comes before purchasing.

Product classification should come before purchasing

Before you accept a bulk offer or agree a minimum, establish what the product is for. Is it ingestible, cosmetic, vape-related or intended for another use? The answer decides which documents matter and whether the line belongs in a French professional list at all.

If a supplier presents an oil as a food or food supplement, ask for the Novel Food status in writing. If no authorisation exists, treat that as a commercial stop, not as a paperwork detail to resolve later.

EFSA’s work is not a Novel Food authorisation

The European Food Safety Authority, or EFSA, plays a central role in scientific assessment within the EU Novel Food process. On 9 February 2026, EFSA published a provisional safe intake level for highly purified CBD for certain food-supplement formulations with CBD purity of at least 98%, subject to manufacturing and safety conditions. This was not a general safe dose for all CBD products.

That publication was not a Novel Food market authorisation. EFSA also identified unresolved uncertainties relating to liver, endocrine, nervous-system and reproductive safety. Its provisional conclusion explicitly excluded people under 25, pregnant or breastfeeding women, and people taking medication from any safety conclusion.

For a CBD supplier or reseller, this difference is essential. A scientific opinion, a provisional intake figure, a toxicology summary and a formal authorisation are not interchangeable documents. Commercial teams should avoid describing an EFSA publication as approval for CBD oils, gummies or other food products.

Verify any claimed food authorisation against the European Commission’s Union list and its conditions of use. An application, safety assessment or history of sale is not equivalent to an authorisation covering the proposed product.

Building a compliance-focused wholesale catalogue

For B2B operators, the Novel Food issue has direct consequences for assortment planning, purchasing commitments and customer communication. It can affect which formats are included in a professional list, how products are grouped online and the claims that sales teams are permitted to make.

A sensible review process separates commercial interest from regulatory readiness. Before accepting a bulk offer or agreeing a minimum order quantity, request the available technical documentation and check whether the format is ingestible, cosmetic, vape-related or intended for another use. Where a proposed food product is concerned, documentation should not be presented as proof that Novel Food requirements have been satisfied unless a valid authorisation can be independently confirmed.

Avoiding high-risk cannabinoid assumptions in France

Novel Food is not the only regulatory consideration for a French CBD catalogue. H4CBD, H2CBD, THCP, HHC, HHC-O, HHCP and related semi-synthetic or hydrogenated cannabinoid derivatives have been classified as narcotics by the French medicines agency, ANSM, through measures introduced from 2023 onward.

Their production, sale, possession and use are illegal in France. Do not treat an unfamiliar cannabinoid as an ordinary wholesale opportunity because demand looks strong.

Practical checks before adding a CBD product line

Before adding a line:

• Name the intended use and the destination market
• Confirm whether the format is ingestible
• Ask for Novel Food status where food or food-supplement presentation is involved
• Keep lab documents and batch references for composition and traceability, without treating them as market authorisation
• Check the ANSM position on any derivative cannabinoid before you commit stock

This information is provided for general informational purposes only and does not constitute legal, tax or regulatory advice. Professional buyers should verify current requirements with a qualified advisor or the relevant competent authority before making commercial decisions.